These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

238 related items for PubMed ID: 12629823

  • 1. Medicare prescription plan, threat to AWP could impact the ESRD drug market.
    Neumann ME.
    Nephrol News Issues; 2003 Jan; 17(2):16-7, 21. PubMed ID: 12629823
    [No Abstract] [Full Text] [Related]

  • 2. AWP reimbursement scrutinized by several states.
    Carroll J.
    Manag Care; 2003 Apr; 12(4):11-2. PubMed ID: 12747021
    [No Abstract] [Full Text] [Related]

  • 3. Prescription drugs in Medicare and the ESRD program.
    Powe NR.
    Semin Nephrol; 2000 Nov; 20(6):535-42. PubMed ID: 11111855
    [Abstract] [Full Text] [Related]

  • 4. Increasing generic drug use in Medicare Part D: the role of government.
    Kohl H, Shrank WH.
    J Am Geriatr Soc; 2007 Jul; 55(7):1106-9. PubMed ID: 17608887
    [No Abstract] [Full Text] [Related]

  • 5. Lessons for Medicare Part D in the hemodialysis community.
    Nayeem AI, Chertow GM.
    BMC Nephrol; 2006 Jul 06; 7():11. PubMed ID: 16824211
    [Abstract] [Full Text] [Related]

  • 6. MEDICARE Rx...help is on the way!
    Frankenburger J.
    Colo Nurse; 2005 Sep 06; 105(3):22. PubMed ID: 16189957
    [No Abstract] [Full Text] [Related]

  • 7. Medicare prescription drug coverage (part D): challenges and opportunities.
    Witten B.
    Nephrol News Issues; 2006 Aug 06; 20(9):14-6, 18. PubMed ID: 16916055
    [No Abstract] [Full Text] [Related]

  • 8. Potential impact of Medicare Part D in the end-stage renal disease population.
    St Peter WL.
    Adv Chronic Kidney Dis; 2008 Apr 06; 15(2):140-6. PubMed ID: 18334238
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Save green, go generic: be prepared to answer the $4 question.
    Hansen D.
    S D Med; 2009 Nov 06; 62(11):436-7. PubMed ID: 20128174
    [No Abstract] [Full Text] [Related]

  • 15. Who should be paying for vitamin D analogues--Medicare or the patients?
    Hall G.
    Nephrol Nurs J; 2006 Nov 06; 33(3):345-6, 351. PubMed ID: 16859205
    [No Abstract] [Full Text] [Related]

  • 16. GAO looks at bundling outside ESRD.
    Neumann ME.
    Nephrol News Issues; 2011 Apr 06; 25(4):8. PubMed ID: 21542505
    [No Abstract] [Full Text] [Related]

  • 17. The economics of prescription drug prices, government intervention, and the importation of drugs from Canada.
    Openshaw MS.
    Nurs Econ; 2005 Apr 06; 23(6):307-11, 279. PubMed ID: 16459902
    [Abstract] [Full Text] [Related]

  • 18. [Prescriptions for psychotropic drugs: results and comments on the 2005 prescription drug report].
    Fritze J.
    Nervenarzt; 2006 Mar 06; 77(3):376-83. PubMed ID: 17078120
    [No Abstract] [Full Text] [Related]

  • 19. [[Prescriptions for psychotropic drugs: results and comments on the 2007 prescription drug report].
    Fritze J.
    Nervenarzt; 2008 Nov 06; 79(11):1337-45. PubMed ID: 19002733
    [No Abstract] [Full Text] [Related]

  • 20. MNT essential to plans for adding prescription drug benefit to Medicare.
    Larson E.
    J Am Diet Assoc; 2000 Aug 06; 100(8):881-2. PubMed ID: 10955040
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.